Is the company's energy focused on volume sales presently, or have they dropped it back a gear to ensure best of breed, develop the data further and produce clinical trial results ?
There are other items that you haven't considered, such as when and what volume will the WA subsidy deal contribute, how easy and cheap is it for women to obtain etc. How close are the other states and what data do they need to come onboard etc
I'm not impressed with the sales, but what they are doing in the background is where the real value is at. If they get a mention from the FDA and produce positive clinical trials, coupled with multiple government subsidy programs, the sales volume will far outdo what it would have achieved had they not take additional steps
I would suggest calling the company to ask the particulars
ALT Price at posting:
0.5¢ Sentiment: Buy Disclosure: Held